Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H38O |
| Molecular Weight | 330.5472 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 3 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C
InChI
InChIKey=HUCXKZBETONXFO-NJFMWZAGSA-N
InChI=1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17+
| Molecular Formula | C23H38O |
| Molecular Weight | 330.5472 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 3 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pubmed/26345206
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pubmed/26345206
Tetraprenylacetone (Geranylgeranylacetone) is an anti-peptic ulcer drug developed and approved in Japan in 1984. Tetraprenylacetone is shown to suppress H. pylori induced tissue and cell injury and inflammatory reaction, so it is expected to show beneficial effects on H. pylori-infected tissues. Tetraprenylacetone is used to treat patients suffering from peptic ulcers and gastritis. In Japan it is sold under the brand name Selbex.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map04210 |
|||
Target ID: Chaperone protein DnaK Helicobacter pylori NCTC 11637 ATCC 43504 |
0.076 mM [Kd] | ||
Target ID: CHEMBL5460 |
0.02 mM [Kd] | ||
Target ID: CHEMBL2157 |
|||
Target ID: Hsp70 [Homo sapiens] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Selbex Approved UseImprovement of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases:
Acute gastritis and acute exacerbation stage of chronic gastritis and Gastric ulcers Launch Date1984 |
|||
| Primary | Selbex Approved UseImprovement of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases:
Acute gastritis and acute exacerbation stage of chronic gastritis and Gastric ulcers Launch Date1984 |
Sample Use Guides
Capsules 50 mg:
The usual adult dosage for oral use is 3 capsules (150 mg
of teprenone) daily in three divided doses after meals.
The dosage may be adjusted depending on the patient’s
age and symptoms.
Fine Granules 10%:
The usual adult dosage for oral use is 1.5 g (150 mg of
teprenone) daily in three divided doses after meals. The
dosage may be adjusted depending on the patient’s age
and symptoms.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:39:56 GMT 2023
by
admin
on
Fri Dec 15 15:39:56 GMT 2023
|
| Record UNII |
57B67OXM8F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
57B67OXM8F
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
3796-63-2
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY | |||
|
5282199
Created by
admin on Fri Dec 15 15:39:57 GMT 2023 , Edited by admin on Fri Dec 15 15:39:57 GMT 2023
|
PRIMARY |